Toothy AI vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Toothy AI is a dental AI platform that uses computer vision to analyze dental X-rays, helping dentists detect cavities, bone loss, and other dental pathology more accurately. HQ: San Francisco.
About
Toothy AI is a dental AI company applying computer vision to the analysis of dental radiographs (bitewing X-rays, periapical X-rays, panoramic scans), helping dentists detect caries (cavities), bone loss, failing restorations, and other pathology more reliably and consistently. Dental AI image analysis is a high-value application: dental X-rays are taken at virtually every dental visit, the findings have direct treatment implications, and research has shown that dentists' detection rates for early-stage caries can vary significantly based on experience and reading conditions.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.